Literature DB >> 23197731

Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor.

Ryoichi Kimura1, David MacTavish, Jing Yang, David Westaway, Jack H Jhamandas.   

Abstract

Alzheimer's disease (AD) is characterized by accumulation of amyloid-β peptide (Aβ) in the brain regions that subserve memory and cognition. The amylin receptor is a potential target receptor for expression of the deleterious actions of soluble oligomeric Aβ species. We investigated whether the amylin receptor antagonist, AC253, neutralizes the depressant effects of Aβ(1-42) and human amylin on hippocampal long-term potentiation (LTP). Furthermore, we examined whether depressed levels of LTP observed in transgenic mice, which overexpress amyloid precursor protein (TgCRND8), could be restored with AC253. In mouse hippocampal brain slices, field EPSPs were recorded from the stratum radiatum layer of the CA1 area (cornu ammonis 1 region of the hippocampus) in response to electrical stimulation of Schaeffer collateral afferents. LTP was induced by 3-theta burst stimulation protocols. Aβ(1-42) (50 nM) and human amylin (50 nM), but not Aβ(42-1) (50 nM), depressed LTP evoked using both stimulation protocols. Preapplication of AC253 (250 nM) blocked Aβ- and human amylin-induced reduction of LTP without affecting baseline transmission or LTP on its own. In contrast to wild-type controls, where robust LTP is observed, 6- to 12-month-old TgCRND8 mice show blunted LTP that is significantly enhanced by application of AC253. Our data demonstrate that the effects of Aβ(1-42) and human amylin on LTP are expressed via the amylin receptor, and moreover, blockade of this receptor increases LTP in transgenic mice that show increased brain amyloid burden. Amylin receptor antagonists could serve as potentially useful therapeutic agents in AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23197731      PMCID: PMC6621862          DOI: 10.1523/JNEUROSCI.3028-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  23 in total

1.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice.

Authors:  P F Chapman; G L White; M W Jones; D Cooper-Blacketer; V J Marshall; M Irizarry; L Younkin; M A Good; T V Bliss; B T Hyman; S G Younkin; K K Hsiao
Journal:  Nat Neurosci       Date:  1999-03       Impact factor: 24.884

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.

Authors:  M A Chishti; D S Yang; C Janus; A L Phinney; P Horne; J Pearson; R Strome; N Zuker; J Loukides; J French; S Turner; G Lozza; M Grilli; S Kunicki; C Morissette; J Paquette; F Gervais; C Bergeron; P E Fraser; G A Carlson; P S George-Hyslop; D Westaway
Journal:  J Biol Chem       Date:  2001-03-15       Impact factor: 5.157

Review 4.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

5.  In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.

Authors:  W Blaine Stine; Karie N Dahlgren; Grant A Krafft; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

6.  Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors.

Authors:  James H Chin; Li Ma; David MacTavish; Jack H Jhamandas
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

7.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

Authors:  Igor Klyubin; Dominic M Walsh; Cynthia A Lemere; William K Cullen; Ganesh M Shankar; Vicki Betts; Edward T Spooner; Liying Jiang; Roger Anwyl; Dennis J Selkoe; Michael J Rowan
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

8.  Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice.

Authors:  Arianna Bellucci; Ilaria Luccarini; Carla Scali; Costanza Prosperi; Maria Grazia Giovannini; Giancarlo Pepeu; Fiorella Casamenti
Journal:  Neurobiol Dis       Date:  2006-08       Impact factor: 5.996

9.  In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain.

Authors:  G Paxinos; S Y Chai; G Christopoulos; X-F Huang; A W Toga; H Q Wang; P M Sexton
Journal:  J Chem Neuroanat       Date:  2004-07       Impact factor: 3.052

10.  Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons.

Authors:  Jack H Jhamandas; David MacTavish
Journal:  J Neurosci       Date:  2004-06-16       Impact factor: 6.167

View more
  29 in total

Review 1.  The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Authors:  John Grizzanti; Hyoung-Gon Lee; Antoni Camins; Merce Pallas; Gemma Casadesus
Journal:  Nutr Res       Date:  2016-11-08       Impact factor: 3.315

Review 2.  Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.

Authors:  Wei Qiao Qiu
Journal:  Neuroscience       Date:  2017-05-19       Impact factor: 3.590

Review 3.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

4.  Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin.

Authors:  Jill K Morris; Eric D Vidoni; Jonathan D Mahnken; Robert N Montgomery; David K Johnson; John P Thyfault; Jeffrey M Burns
Journal:  Neurobiol Aging       Date:  2015-12-01       Impact factor: 4.673

5.  Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid β-Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss.

Authors:  Ronald K Freund; Emily S Gibson; Huntington Potter; Mark L Dell'Acqua
Journal:  Mol Pharmacol       Date:  2016-03-08       Impact factor: 4.436

Review 6.  Is Alzheimer's disease a systemic disease?

Authors:  Jill K Morris; Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  Biochim Biophys Acta       Date:  2014-04-18

7.  Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.

Authors:  R Kimura; D MacTavish; J Yang; D Westaway; Jack H Jhamandas
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

8.  SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model.

Authors:  Erin Knock; Shinsuke Matsuzaki; Hironori Takamura; Kanayo Satoh; Grace Rooke; Kyung Han; Hong Zhang; Agnieszka Staniszewski; Taiichi Katayama; Ottavio Arancio; Paul E Fraser
Journal:  Neurobiol Dis       Date:  2017-12-05       Impact factor: 7.046

Review 9.  Growth factors in synaptic function.

Authors:  Vivian Y Poon; Sojoong Choi; Mikyoung Park
Journal:  Front Synaptic Neurosci       Date:  2013-09-18

10.  Lessons from two prevalent amyloidoses-what amylin and Aβ have in common.

Authors:  Jürgen Götz; Yun-An Lim; Anne Eckert
Journal:  Front Aging Neurosci       Date:  2013-08-08       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.